Liu W, Qdaisat A, Ferrarotto R, et al. - Among patients suffering from head and neck cancer who were treated with concurrent chemoradiation with weekly infusions of cisplatin and/or carboplatin, the link between hypomagnesemia and survival was investigated retrospectively. Patients (aged ≥18 years) with squamous cell carcinoma of the larynx, oral cavity, or oropharynx treated with at least 30 fractions of radiotherapy with concurrent weekly cisplatin and/or carboplatin were included. Independent of age, cancer site, Eastern Cooperative Oncology Group performance status, and smoking history, a significant link was identified between a greater frequency of hypomagnesemia during the treatment course and shorter survival. Also, shorter survival was observed in relation to more severe hypomagnesemia vs the milder form. Overall, in this patient population, frequency and severity of hypomagnesemia during treatment were identified as prognostic factors for survival.